Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: A randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet Diabetes and Endocrinology

Volumn 1, Issue 3, 2013, Pages 208-219

  Roden, Michael ^a,b   Weng, Jianping ^c   Eilbracht, Jens ^d   Delafont, Bruno ^e   Kim, Gabriel ^d   Woerle, Hans J ^d   Broedl, Uli C ^d  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

^c THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^e BOEHRINGER INGELHEIM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EMPAGLIFLOZIN; HEMOGLOBIN A1C; PLACEBO; SITAGLIPTIN; BENZHYDRYL DERIVATIVE; GLUCOSIDE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; PYRAZINE DERIVATIVE; SODIUM GLUCOSE COTRANSPORTER 2; TRIAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; GENITAL TRACT INFECTION; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HEMATOCRIT; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; URINARY TRACT INFECTION; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; ANALYSIS OF VARIANCE; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; MIDDLE AGED;

ANALYSIS OF VARIANCE; BENZHYDRYL COMPOUNDS; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLOMERULAR FILTRATION RATE; GLUCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; PYRAZINES; SODIUM-GLUCOSE TRANSPORTER 2; TRIAZOLES;

EID: 84885954870     PISSN: 22138587     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-8587(13)70084-6     Document Type: Article

References (19)

1. DeFronzo RA, Davidson JA, del Prato S The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab 2012, 14:5-14.
2. List JF, Whaley JM Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans. Kidney Int Suppl 2011, 120:S20-S27.
3. Grempler R, Thomas L, Eckhardt M, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 2012, 14:83-90.
4. Ferrannini E, Seman L, Seewaldt-Becker E, Hantel S, Pinnetti S, Woerle H A phase IIb, randomised, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes Metab 2013, 15:721-728.
5. Rosenstock J, Seman LJ, Jelaska A, et al. Efficacy and safety of empagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycemia. Diabetes Obes Metab 2013, published online Aug 1. 10.1111/dom.12185.
6. Häring H-U, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin for 24 weeks improves glycemic control in patients with type 2 diabetes (T2DM). Diabetes 2013, 62(suppl 1):A282.
7. Häring H-U, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week randomized, double-blind, placebo-controlled trial. Diabetes Care 2013, published online Aug 20. 10.2337/dc12-2673.
8. Kovacs CS, Seshiah V, Swallow R, et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 2013, published online Aug 1. 10.1111/dom.12188.
9. Rosenstock J, Jelaska A, Wang F, Kim G, Broedl U, Woerle H-J Empagliflozin as add-on to basal insulin for 78 weeks improves glycemic control with weight loss in insulin-treated type 2 diabetes (T2DM). Diabetes 2013, 62(suppl 1):A285.
10. Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013, published online April 5. 10.2337/dc12-2491.
11. Hauber AB, Mohamed AF, Johnson FR, Falvey H Treatment preferences and medication adherence of people with type 2 diabetes using oral glucose-lowering agents. Diabet Med 2009, 26:416-424.
12. Bogelund M, Vilsboll T, Faber J, Henriksen JE, Gjesing RP, Lammert M Patient preferences for diabetes management among people with type 2 diabetes in Denmark-a discrete choice experiment. Curr Med Res Opin 2011, 27:2175-2183.
13. Fujioka K, Seaton TB, Rowe E, et al. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2000, 2:175-187.
14. Lavie CJ, Milani RV, Artham SM, Patel DA, Ventura HO The obesity paradox, weight loss, and coronary disease. Am J Med 2009, 122:1106-1114.
15. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360:1903-1913.
16. A phase III, multicentre, international, randomised, parallel group, double blind cardiovascular safety study of BI 10773 (10 mg and 25 mg administered orally once daily) compared to usual care in type 2 diabetes mellitus patients with increased cardiovascular risk Boehringer Ingelheim, (accessed Aug 27, 2013). http://clinicaltrials.gov/ct2/show/NCT01131676.
17. Stenlof K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013, 15:372-382.
18. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010, 33:2217-2224.
19. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012, 35:1364-1379.